


PHARMACEUTICAL 2018

ESPERION

Esperion Therapeutics Inc. Rank 108 of 342





PHARMACEUTICAL 2018

ESPERION

Esperion Therapeutics Inc. Rank 108 of 342

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 117% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	203,924
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	33,144
Liabilities, Non-Current	0
Other Assets	73,476
Other Compr. Net Income	-673
Other Expenses	198
Other Liabilities	0
Other Net Income	2,192
Other Revenues	0
Property and Equipment	435
Research and Development	147,603
Selling, General and Administrative Expense	21,379

Output Variable	Value in 1000 USD
Assets	277,835
Liabilities	33,144
Expenses	169,180
Revenues	0
Stockholders Equity	244,691
Net Income	-166,988
Comprehensive Net Income	-167,324
Economic Capital Ratio	163%

